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Budesonide MMX and Mesalamine to
Induce Remission in Patients With
Ulcerative Colitis
Dear Sir:
We read with interest about the randomized, controlled
trial (RCT) by Sandborn et al,1 which deserve some com-
ments concerning the methodology and the interpreta-
tion of the results.
First, the authors compared the efficacy of Budes-
onide MMX (9 and 6 mg/d) with mesalamine 2.4 g/d or
placebo to induce remission in patients with active
mild to moderate ulcerative colitis (UC). When a new
drug must be evaluated versus an old treatment, the
main rule is to choose the most appropriate dosage of
the comparison drug. In 1987, Schroeder et al2 showed
hat oral 5-aminosalicylic acid therapy in a dosage of
.8 g/d was an effective therapy to induce remission in
ctive UC. Two successive metaanalyses of the all RCTs
f mesalamine confirmed that 3 g/d are needed to
chieve the best result.3,4 Therefore, the comparison in
this trial was not appropriate.
Second, the clinical and combined remission (clinical
and endoscopic) data observed in this study with me-
salamine tablets (34% and 12%, respectively) are at vari-
ance with those of published RCTs. Leifeld et al,5 in a
ooled analysis of 4 RCTs of 3 g/d of mesalamine,
howed that tablets were able to obtain a clinical re-
ission in 71% and endoscopic remission in 48% of
atients. In the discussion, the authors state that me-
alamine 2.4 g/d is not more effective than placebo,
hen this statement seems debatable according to the
nalysis previously quoted.5
Considering that mesalamine is an effective drug in
mild-to-moderate, active UC, before introducing budes-
onide MMx as a standard treatment for mild to mod-
erate UC, it is advisable to design a trial which compare
budesonide MMX with an effective dose of mesalamine.
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Reply. We appreciated Criscuoli, Sinagra, and Cottone’s
comments regarding our manuscript, “Once-Daily Budes-
onide MMX Extended-Release Tablets Induce Remission
in Patients with Mild to Moderate Ulcerative Colitis: Re-
sults from the CORE I Study.”1 Their primary concern
urrounds the dose of Asacol utilized in the study (2.4
/d) and the performance of the drug in the clinical trial
hat was designed to examine the efficacy of MMX budes-
nide for mild to moderately active ulcerative colitis.
There is now abundant evidence that there are not
linically important differences in dose response between
.4 and 4.8 g/d for the 2 different dose forms of delayed-
elease mesalamine, Asacol2–4 and Lialda,5,6 in patients
with mild to moderately active ulcerative colitis. Based on
these large, randomized, controlled trials and the original
trial by Sninsky et al,7 which showed that Asacol at doses
f both 1.6 and 2.4 g/d was more effective than placebo,
e believe that Asacol 2.4 g/d is an effective dose.
Furthermore, the primary goals of our study were to
emonstrate the efficacy of budesonide MMX relative to
lacebo and to establish a dose response. Those goals were
chieved in this study. The nonpowered Asacol reference
rm was included at the request of European regulatory
uthorities, and was the approved dose at the time the
tudy protocol was designed and approved. The study was
ot powered to demonstrate either superiority or nonin-
eriority of Asacol relative to MMX budesonide; therefore,
o conclusions can be drawn regarding the relative effi-
acy of these 2 agents. Last, the trial was not powered to
emonstrate the superiority of Asacol relative to placebo;
herefore, no conclusions can be from our data regarding
he efficacy of Asacol.
We stand by the conclusion of our study, that budes-
nide MMX 9 mg/d is effective for induction of remission
n patients with mild to moderately active ulcerative coli-
is.
WILLIAM J. SANDBORN
University of California San Diego
La Jolla, California
SIMON TRAVIS
Radcliff Infirmary
Oxford University
Oxford, UK
DAVID BALLARD
Santarus
Del Mar, California
